Wave Life Sciences WVE
- Market cap
- $694.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 9.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $70.9M
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −30.0%
Wave Life Sciences trades at 9.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $70.9M over the last twelve months.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $29.1M+2245% | $12.5M−3% | $19.7M−11% | n/a | n/a | $9.2M−27% | $8.7M−56% | $7.6M | $17.2M | $38.2M+317% | $2.3M−74% | $13.2M+73% | |
| R&D | $34.1M+10% | $33.4M+8% | $40.4M+21% | $41.2M+30% | $44.6M+31% | $40.6M+22% | $43.5M+8% | $45.9M+11% | $52.8M+18% | $47.4M+17% | $51.3M+18% | $53.8M+17% |
| SG&A | $13.7M−0% | $13.5M+11% | $14.3M+17% | $15M+15% | $16.1M+18% | $18.4M+36% | $18M+26% | $18.1M+20% | $20.9M+30% | $22.1M+20% | $24.8M+38% | $25.4M+40% |
| −$18.7M−57% | −$34.5M+14% | −$35M+49% | −$63.9M | $23M | −$49.8M+45% | −$52.8M+51% | −$56.4M−12% | −$56.5M | −$31.3M−37% | −$73.8M+40% | −$66M+17% | |
| Pre-tax income | −$16.3M−62% | −$31.6M+15% | −$32.9M+56% | −$61.8M | $29.3M | −$46.9M+49% | −$50.5M+53% | −$53.9M−13% | −$53.2M | −$26.1M−44% | −$69.4M+37% | −$61.9M+15% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$16.3M−63% | −$31.6M+15% | −$32.9M+56% | −$61.8M | $29.3M | −$46.9M+49% | −$50.5M+53% | −$53.9M−13% | −$53.2M | −$26.1M−44% | −$69.4M+37% | −$61.9M+15% |
| −$0.15−68% | −$0.24−11% | −$0.25+25% | −$0.47 | $0.18 | −$0.29+21% | −$0.31+24% | −$0.32−32% | −$0.30 | −$0.13−55% | −$0.34+10% | −$0.30−6% | |
| 110.8M+18% | 129.3M+27% | 129.5M+23% | 132.6M+24% | 161.5M+46% | 162.6M+26% | 164M+27% | 167.7M+27% | 180.2M+12% | 200.2M+23% | 204M+24% | 204.2M+22% |
EPS, diluted: 8 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| WVEWave Life Sciences | $694.2M | n/m | n/a | 9.8× | n/m | n/m | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| Peer median | $685.3M | 11.3× | 13.5× | 1.6× | +14% | 22.5% |
Investors who own it
Investors we follow who held Wave Life Sciences at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.5% of portfolioadded
- Stanley DruckenmillerDuquesne Family Office0.0% of portfolio
More on Wave Life Sciences
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .